%0 Journal Article %A Blake Martin %A Peter E. DeWitt %A Seth Russell %A Adit Anand %A Katie R. Bradwell %A Carolyn Bremer %A Davera Gabriel %A Andrew T. Girvin %A Janos G. Hajagos %A Julie A. McMurry %A Andrew J. Neumann %A Emily R. Pfaff %A Anita Walden %A Jacob T. Wooldridge %A Yun Jae Yoo %A Joel Saltz %A Ken R. Gersing %A Christopher G. Chute %A Melissa A. Haendel %A Richard Moffitt %A Tellen D. Bennett %T Children with SARS-CoV-2 in the National COVID Cohort Collaborative (N3C) %D 2021 %R 10.1101/2021.07.19.21260767 %J medRxiv %P 2021.07.19.21260767 %X Importance SARS-CoV-2Objective To determine the characteristics, changes over time, outcomes, and severity risk factors of SARS-CoV-2 affected children within the National COVID Cohort Collaborative (N3C)Design Prospective cohort study of patient encounters with end dates before May 27th, 2021.Setting 45 N3C institutionsParticipants Children <19-years-old at initial SARS-CoV-2 testingMain Outcomes and Measures Case incidence and severity over time, demographic and comorbidity severity risk factors, vital sign and laboratory trajectories, clinical outcomes, and acute COVID-19 vs MIS-C contrasts for children infected with SARS-CoV-2.Results 728,047 children in the N3C were tested for SARS-CoV-2; of these, 91,865 (12.6%) were positive. Among the 5,213 (6%) hospitalized children, 685 (13%) met criteria for severe disease: mechanical ventilation (7%), vasopressor/inotropic support (7%), ECMO (0.6%), or death/discharge to hospice (1.1%). Male gender, African American race, older age, and several pediatric complex chronic condition (PCCC) subcategories were associated with higher clinical severity (p≤0.05). Vital signs (all p≤0.002) and many laboratory tests from the first day of hospitalization were predictive of peak disease severity. Children with severe (vs moderate) disease were more likely to receive antimicrobials (71% vs 32%, p<0.001) and immunomodulatory medications (53% vs 16%, p<0.001).Compared to those with acute COVID-19, children with MIS-C were more likely to be male, Black/African American, 1-to-12-years-old, and less likely to have asthma, diabetes, or a PCCC (p<0.04). MIS-C cases demonstrated a more inflammatory laboratory profile and more severe clinical phenotype with higher rates of invasive ventilation (12% vs 6%) and need for vasoactive-inotropic support (31% vs 6%) compared to acute COVID-19 cases, respectively (p<0.03).Conclusions In the largest U.S. SARS-CoV-2-positive pediatric cohort to date, we observed differences in demographics, pre-existing comorbidities, and initial vital sign and laboratory test values between severity subgroups. Taken together, these results suggest that early identification of children likely to progress to severe disease could be achieved using readily available data elements from the day of admission. Further work is needed to translate this knowledge into improved outcomes.Competing Interest StatementDr. Bennett reported receiving grants from the National Institutes of Health (NIH)/National Center for Advancing Translational Sciences (NCATS) during the conduct of the study and grants from the NIH/Eunice Kennedy Shriver National Institute of Child Health and Human Development and NIH/National Institute of Allergy and Infectious Diseases outside the submitted work. Dr. Moffitt reported receiving grants from the NIH during the conduct of the study. Dr. Hajagos reported receiving grants from the NIH/NCATS during the conduct of the study. Dr. Bradwell reported being employed by Palantir Technologies during the conduct of the study and outside the submitted work. Ms. Gabriel reported receiving grants from the NIH/NCATS during the conduct of the study. Dr. Girvin reported being an employee of Palantir Technologies. Ms. McMurry reported being a cofounder of Pryzm Health outside the submitted work. Dr. Pfaff reported receiving grants from the NIH/NCATS during the conduct of the study. Dr. Haendel reported receiving grants from the NIH during the conduct of the study. Dr. Chute reported receiving grants from the NIH/NCATS during the conduct of the study. No conflicts of interest reported for all other authors.Funding StatementDeclaration of Interests / Conflict of Interest Disclosures: Dr. Bennett reported receiving grants from the National Institutes of Health (NIH)/National Center for Advancing Translational Sciences (NCATS) during the conduct of the study and grants from the NIH/Eunice Kennedy Shriver National Institute of Child Health and Human Development and NIH/National Institute of Allergy and Infectious Diseases outside the submitted work. Dr. Moffitt reported receiving grants from the NIH during the conduct of the study. Dr. Hajagos reported receiving grants from the NIH/NCATS during the conduct of the study. Dr. Bradwell reported being employed by Palantir Technologies during the conduct of the study and outside the submitted work. Ms. Gabriel reported receiving grants from the NIH/NCATS during the conduct of the study. Dr. Girvin reported being an employee of Palantir Technologies. Ms. McMurry reported being a cofounder of Pryzm Health outside the submitted work. Dr. Pfaff reported receiving grants from the NIH/NCATS during the conduct of the study. Dr. Haendel reported receiving grants from the NIH during the conduct of the study. Dr. Chute reported receiving grants from the NIH/NCATS during the conduct of the study. No conflicts of interest reported for all other authors. Funding / Support: The primary study sponsors are multiple institutes of the U.S. National Institutes of Health. The National Center for Advancing Translational Sciences is the primary steward of the N3C data and created the underlying architecture of the N3C Data Enclave, manages the Data Transfer Agreements and Data Use Agreements, houses the Data Access Committee, and supports contracts to vendors to help build various aspects of the N3C Data Enclave. Employees of the NIH and of the contracting companies are included as authors of the manuscript and participated in the writing and decision to submit the manuscript. The analyses for this work were conducted using data and tools accessed through the NCATS N3C Data Enclave and supported by NCATS U24 TR002306 (Drs Haendel, Chute, and Saltz; also supporting Dr. Pfaff, Ms. Walden, Ms. McMurry, Mr. Neumann and Ms. Gabriel). This study was also supported by numerous institutional grants associated with institutions with release data, see supplement for full list of grant numbers and institutions.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The N3C data transfer to NCATS is performed under a Johns Hopkins University Reliance Protocol # IRB00249128 or individual site agreements with NIH. Use of the N3C data for this study is authorized under the following IRB Protocols: - Site: University of Colorado; IRB Name: Colorado Multiple Institutional Review Board; Exempted vs approved: approved; Protocol Number:20-2225 - Site: Johns Hopkins University; IRB Name: Johns Hopkins Office of Human Subjects Research, Institutional Review Board ; Exempted vs approved: approved; Protocol number: IRB00249128 - Site: University of North Carolina; IRB name: University of North Carolina Chapel Hill Institutional Review Board; Exempted vs approved: exempted; Protocol number: 20-3106 - Site: Stony Brook University; IRB name: Office of Research Compliance, Division of Human Subject Protections, Stony Brook University; Exempted vs approved: exempted; Protocol number: IRB2020-00604All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe N3C Data Enclave (covid.cd2h.org/enclave) houses fully reproducible, transparent, and broadly available limited and de-identified datasets (HIPAA definitions available at https://www.hhs.gov/hipaa/index.html). Enclave data can be accessed by investigators at institutions that have signed a Data Use Agreement with the NIH who have taken the required human subjects and security training and agree to the N3C User Code of Conduct. Those desiring access to the limited dataset need also supply an IRB protocol from their institution. Data access requests are reviewed by the NIH Data Access Committee. A full description of the N3C Enclave governance has been published (https://academic.oup.com/jamia/article/28/3/427/5893482) and additional information on the access application process is available on the NCATS website: https://ncats.nih.gov/n3c/about/applying-for-access. The data model utilized is OMOP 5.3.1, and specifications are available at: https://ncats.nih.gov/files/OMOP_CDM_COVID.pdf Additional N3C resources including code and governance documents are available within the project GitHub repositories and/or in Zenodo for archival purposes: https://github.com/National-COVID-Cohort-Collaborative https://zenodo.org/communities/cd2h-covid/ https://unite.nih.gov/ https://covid.cd2h.org/enclave https://academic.oup.com/jamia/article/28/3/427/5893482 https://ncats.nih.gov/n3c/about/applying-for-access https://ncats.nih.gov/files/OMOP_CDM_COVID.pdf https://github.com/National-COVID-Cohort-Collaborative https://zenodo.org/communities/cd2h-covid/ %U https://www.medrxiv.org/content/medrxiv/early/2021/07/23/2021.07.19.21260767.full.pdf